North America Congestive Heart Failure (CHF) Treatment Devices Market Size, Share & Industry Trends Analysis Report By Product Type (Pacemakers, Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy, and Ventricular Assist Devices), B

North America Congestive Heart Failure (CHF) Treatment Devices Market Size, Share & Industry Trends Analysis Report By Product Type (Pacemakers, Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy, and Ventricular Assist Devices), By Country and Growth Forecast, 2022 – 2028

The North America Congestive Heart Failure (CHF) Treatment Devices Market would witness market growth of 4.9% CAGR during the forecast period (2022-2028).

Congestive heart failure, or CHF, is a chronic progressive condition that impacts the pumping ability of the heart muscle. Congestive heart failure treatment devices are instruments that are used to treat patients with CHF. Mechanical circulatory support devices are used to treat congestive heart failure. Pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy devices, and ventricular assist devices are examples of congestive heart failure therapeutic equipment. Implantable cardiac defibrillators are electronic devices that are implanted into the body. An ICD (implantable cardiac defibrillator) continuously monitors heart rhythm and, if it becomes abnormal, delivers a mild shock to the heart muscle.

A ventricular assist device aids in pumping the blood from the heart's lower chambers to the rest of the body. There are also several types of ventricular assist devices, including left congestive heart failure treatment devices (LVADs), right congestive heart failure treatment devices (RVADs), and others. Because weak left ventricular muscles are widespread among patients with congestive heart failure, left congestive heart failure therapy devices are the most widely utilized VADs. They have been employed as a long-term therapy for people with only a slim likelihood of improving their cardiac muscles. Right congestive heart failure therapy devices (RVADs) pump blood from the right ventricle to the pulmonary aorta. When compared to instances requiring an LVAD, such occurrences are quite uncommon.

Some of the factors driving market expansion in the North American region include increased demand for congestive heart failure (CHF) treatments, high health expenditures, rising prevalence of target illnesses, and increased population awareness regarding treatment device availability. According to the Centers for Disease Control and Prevention, COVID-19 patients with an underlying cardiac issue are still more likely to become severely ill. Moreover, supportive sickness awareness campaigns are anticipated to help the cardiovascular devices market in North America. In addition, according to the National Library of Medicine, CV disorders are a severe health burden for Canadians. About one-third of Canadians die from heart attacks and strokes, and CV diseases account for nearly 16% of hospitalizations.

This illness load has a significant economic impact, with CV disorders accounting for more than $22 billion indirect and direct expenditures in 2000. Despite these figures, the mortality rates for heart attacks and strokes have dropped dramatically in recent decades, and the number of Canadians dying from CV disorders has lately decreased. Some of the risk factors for cardiovascular disease are becoming more common at an alarming rate. Obesity is on the rise, especially among the young, and this is expected to lead to more diabetes, hypertension, and lipid abnormalities, which would result in more heart attacks and strokes.

The US market dominated the North America Congestive Heart Failure (CHF) Treatment Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,234.7 Million by 2028. The Canada market is experiencing a CAGR of 7.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 6.3% during (2022 - 2028).

Based on Product Type, the market is segmented into Pacemakers, Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy, and Ventricular Assist Devices. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, MicroPort Scientific Corporation, Abbott Laboratories, Medtronic PLC, Abiomed, Inc., Berlin Heart GmbH, Jarvik Heart, Inc., Lepu Medical Technology (Beijing) Co., Ltd., BIOTRONIK SE & Co. KG, and Osypka Medical GmbH.

Scope of the Study

Market Segments covered in the Report:

By Product Type

  • Pacemakers
  • Implantable Cardioverter Defibrillators
  • Cardiac Resynchronization Therapy
  • Ventricular Assist Devices
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America
Companies Profiled
  • Boston Scientific Corporation
  • MicroPort Scientific Corporation
  • Abbott Laboratories
  • Medtronic PLC
  • Abiomed, Inc.
  • Berlin Heart GmbH
  • Jarvik Heart, Inc.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • BIOTRONIK SE & Co. KG
  • Osypka Medical GmbH
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Congestive Heart Failure (CHF) Treatment Devices Market, by Product Type
1.4.2 North America Congestive Heart Failure (CHF) Treatment Devices Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Feb) Leading Players
Chapter 4. North America Congestive Heart Failure (CHF) Treatment Devices Market by Product Type
4.1 North America Pacemakers Market by Country
4.2 North America Implantable Cardioverter Defibrillators Market by Country
4.3 North America Cardiac Resynchronization Therapy Market by Country
4.4 North America Ventricular Assist Devices Market by Country
Chapter 5. North America Congestive Heart Failure (CHF) Treatment Devices Market by Country
5.1 US Congestive Heart Failure (CHF) Treatment Devices Market
5.1.1 US Congestive Heart Failure (CHF) Treatment Devices Market by Product Type
5.2 Canada Congestive Heart Failure (CHF) Treatment Devices Market
5.2.1 Canada Congestive Heart Failure (CHF) Treatment Devices Market by Product Type
5.3 Mexico Congestive Heart Failure (CHF) Treatment Devices Market
5.3.1 Mexico Congestive Heart Failure (CHF) Treatment Devices Market by Product Type
5.4 Rest of North America Congestive Heart Failure (CHF) Treatment Devices Market
5.4.1 Rest of North America Congestive Heart Failure (CHF) Treatment Devices Market by Product Type
Chapter 6. Company Profiles
6.1 Boston Scientific Corporation
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Approvals and Trials:
6.1.5.2 Product Launches and Product Expansions:
6.1.5.3 Acquisition and Mergers:
6.2 MicroPort Scientific Corporation
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent Strategies and Developments:
6.2.5.1 Approvals and Trials:
6.2.5.2 Product launches and Product Expansions:
6.3 Abbott Laboratories
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.3.5.2 Approvals and Trials:
6.3.5.3 Acquisitions and Mergers:
6.3.5.4 Product Launches and Product Expansions:
6.4 Medtronic PLC
6.4.1 Company overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 Abiomed, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Approvals and Trials:
6.5.5.2 Acquisition and Mergers:
6.6 Berlin Heart GmbH
6.6.1 Company Overview
6.6.2 Recent strategies and developments:
6.6.2.1 Partnerships, Collaborations, and Agreements:
6.7 Jarvik Heart, Inc.
6.7.1 Company Overview
6.8 Lepu Medical Technology (Beijing) Co., Ltd.
6.8.1 Company Overview
6.9 BIOTRONIK SE & Co. KG
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Partnerships, Collaborations and Agreements:
6.9.2.2 Approvals & Trials:
6.9.2.3 Product Launches and Product Expansions:
6.10. Osypka Medical GmbH
6.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings